Walleye Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
Other funds holding JAZZ
VPM
VCM
EC
Walleye Capital's JAZZ Position: Q1 2026 in Review
Walleye Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 25% in Q1 2026, selling an estimated $4.96M and leaving 87,365 shares worth $16.5M. The position accounts for 0.07% of the portfolio, ranked #244.
Walleye Capital first reported a position in JAZZ in Q1 2019 and has held it in 15 quarters since. The position peaked at $19.7M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Walleye Capital held 87,365 shares of Jazz Pharmaceuticals worth $16.5M as of Q1 2026.
- Walleye Capital sold 28,393 Jazz Pharmaceuticals shares in Q1 2026, an estimated $4.96M.
- Jazz Pharmaceuticals made up 0.07% of Walleye Capital's portfolio in Q1 2026, its #244 holding.
- Walleye Capital first reported a position in Jazz Pharmaceuticals in Q1 2019 and has held it in 15 quarters since.
- Walleye Capital's Jazz Pharmaceuticals position peaked at $19.7M in Q4 2025.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.